Share

Profile & Fundamentals

Vericel Profile & Fundamentals

Name: Vericel financial chart data preview
Creator: iPulse AI
License: https://ipulseai.com/terms

Examine company identity, ownership, reported performance, valuation, balance-sheet resilience, dividends, buybacks, and material corporate events.

Interactive annual & quarterly chartsAI financial reviewsReported source tables

Explore this pageJump to a Profile & Fundamentals section

Explore this research

Profile & Fundamentals contents

Jump directly to any section

Company and Market Context

Company Profile & Ownership

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Burlington, Massachusetts.

Company profile record

Vericel Corp Ord

Common Stock · Health Care · Biotechnology

Official website

Company

Company / asset: Vericel Corp Ord
Security type: Common Stock
Sector: Health Care
Industry: Biotechnology
HQ: 🇺🇸 United States
Head office: 25 Blue Sky Drive, Burlington, MA, United States, 01803

Leadership & scale

Chief executive: Mr. Dominick C. Colangelo Esq.
CEO year born: 1964
Full-time employees: 398
Fiscal year end: December
IPO date: 1997-02-04

Fundamentals snapshot

Updated 2026-09-13

Market Cap: USD 2.0B
P/E: 84.1x
Revenue (Q2 26): USD 77.5M
Profit (Q2 26): USD 2.2M
Dividend Yield: --
Revenue (FY 25): USD 276.3M
Shares in public float: 50.6M
Insider ownership: 1.19%

Reporting & identifiers

Symbol: VCEL.NASDAQ
Listing: 🇺🇸 United States | Dividend Tax: 30%
Ticker Currency: USD
Income Statement Currency: USD
Balance Sheet Currency: USD
Cash Flow Currency: USD
EPS Currency: USD
Contract Type: SPOT
ISIN: US92346J1088
Asset ID: equity_822ed8cd-c3d6-5744-9304-0c7a5de1fc34

Ownership

Shares Outstanding

Shares outstanding

Annual reported shares outstanding. Values in shares.

Top holders

BlackRock Inc7,765,344 shares · 15.16% · Reported 2026-03-31
State Street Corp3,152,130 shares · 6.16% · Reported 2026-03-31
iShares Core S&P Small-Cap ETF3,109,854 shares · 6.07% · Reported 2026-08-31
Congress Asset Management Company, LLP2,916,295 shares · 5.70% · Reported 2026-06-30
Vanguard Capital Management, LLC2,230,756 shares · 4.36% · Reported 2026-03-31
Conestoga Capital Advisors, LLC2,083,832 shares · 4.07% · Reported 2026-06-30
William Blair Investment Management, LLC1,992,855 shares · 3.89% · Reported 2026-06-30

View more holders (8)

BNP Paribas Investment Partners SA1,723,572 shares · 3.37% · Reported 2026-03-31
Vanguard MStar Total Stk Mkt Idx Invest1,625,279 shares · 3.17% · Reported 2026-07-31
GW&K Investment Management, LLC1,616,855 shares · 3.16% · Reported 2026-03-31
Soleus Capital Management, L.P.1,459,152 shares · 2.85% · Reported 2026-06-30
Geneva Capital Management1,339,123 shares · 2.62% · Reported 2026-06-30
iShares Russell 2000 ETF1,317,598 shares · 2.57% · Reported 2026-08-31
State Street® SPDR® S&P® Biotech ETF1,260,285 shares · 2.46% · Reported 2026-08-31
Geode Capital Management, LLC1,254,862 shares · 2.45% · Reported 2026-03-31

Earnings, Profitability & Valuation

Earnings & Revenue

AI Review

The company is showing a very strong financial turnaround, moving from a phase of losing money to generating significant profits. Recent reports highlight a massive 30% jump in sales, driven by strong demand for its joint-repair and burn-care treatments. More importantly, the company is now generating substantial free cash flow, which means it has plenty of cash left over after paying its bills. Analysts agree that this financial health is highly sustainable because the company does not rely on debt. However, there is some disagreement about how quickly these profits will grow in the near term. Some believe that high stock-based compensation and factory depreciation costs will temporarily hide the company's true earning power, while others expect a rapid and clean surge in net income. Overall, the financial trend is highly positive and provides a strong safety net.

Revenue, Net Income, and Free Cash Flow

Revenue
Free cash flow
Net income

Annual reported financial results, converted using the statement's recorded USD conversion. Missing values are omitted. Values in USD.

Valuation

Historical P/E Ratio

Published P/E

Published valuation snapshots. Trailing four-quarter earnings where available; annual earnings otherwise. Non-positive earnings are omitted. Values in times earnings.

Profitability & Margins

AI Review

The company boasts outstanding profit margins, keeping about 74% of its revenue as gross profit, which shows incredible pricing power. Analysts agree that these high margins are a major strength, but they disagree on how operating margins will behave in the near future. Some warn that the costs of expanding the sales team and depreciating the new factory will temporarily squeeze operating profits, making the stock look artificially expensive. Others argue that as sales volumes grow, these fixed costs will be easily absorbed, leading to a rapid and dramatic expansion in overall profitability. Despite these differing views on the short-term timing, there is strong consensus that the company's underlying business model is highly profitable. The high gross margin floor ensures that as the business scales up, it will eventually mature into a highly efficient cash-printing machine.

Profitability Margins

Gross margin
Operating margin
Net margin
Free cash flow margin

Annual gross, operating, net income and free cash flow divided by revenue for matching reporting dates. Values in percent.

Complete Research Workspace

Unlock the complete Profile & Fundamentals

Sign in to verify your access, or upgrade to the Base plan to open the complete profile & fundamentals and available source data.

Sign in to check access View Base plan

Paywalled preview begins: Reported Data Tables — chart preview

From this section to the end-of-preview notice below, research is provided as simplified HTML text and tables. Full access provides the complete interactive interface, charts and additional datasets.

Reported Data Tables — chart preview

The following tables contain the same values as the financial charts above. Monetary values are USD; margins are percentages. Missing inputs are not estimated. Use is subject to the iPulse AI Terms of Service and applicable source rights.

Source: eodhd. Statement snapshots with chart transformations and ratios calculated by iPulse AI. Snapshot retrieved 2026-09-15.

Annual earnings and profitability
Period end	Revenue	Free cash flow	Net income	Gross margin	Operating margin	Net margin	Free cash flow margin
2016-12-31	54,383,000	-21,307,000	-19,566,000	47.95	-35.39	-35.98	-39.18
2017-12-31	63,924,000	-14,693,000	-17,286,000	52.52	-23.44	-27.04	-22.99
2018-12-31	90,857,000	-3,090,000	-8,137,000	64.6	-4.3	-8.96	-3.4
2019-12-31	117,850,000	-9,799,000	-9,665,000	68.12	-9.55	-8.2	-8.31
2020-12-31	124,179,000	14,946,000	2,864,000	67.83	1.91	2.31	12.04
2021-12-31	156,184,000	21,125,000	-7,471,000	67.88	-5.03	-4.78	13.53
2022-12-31	164,365,000	10,091,000	-16,709,000	66.8	-10.38	-10.17	6.14
2023-12-31	197,516,000	7,798,000	-3,182,000	68.64	-3.27	-1.61	3.95
2024-12-31	237,224,000	-5,811,000	10,362,000	72.55	1.9	4.37	-2.45
2025-12-31	276,259,000	24,748,000	16,518,000	74.42	4	5.98	8.96

Published valuation snapshots
Period end	P/E (times earnings)	Earnings basis
2025-12-31	113.52	Trailing four quarters
2024-12-31	276.67	Trailing four quarters

Shares outstanding — chart values
Reporting date	Shares outstanding
2017-01-01	36,150,000
2018-01-01	46,153,000
2019-01-01	46,803,000
2020-01-01	48,101,000
2021-01-01	49,939,000
2022-01-01	49,204,000
2023-01-01	50,512,000
2024-01-01	52,210,000
2025-01-01	52,071,000
2026-01-01	50,925,000

End of the paywalled preview

The excerpt from Reported Data Tables — chart preview to this notice is the simplified paywalled content included on this page. A signed-in, verified account with the required subscription provides the full interactive interface and the additional research, datasets and tools listed below.

Those additional materials are not included in this preview and cannot be revealed by removing its visual restrictions.

Additional with full access

Earnings, Profitability & Valuation
- Complete profitability ratios
- EPS history and estimate comparisons
- Execution vs expectations
- Annual and quarterly financial views
Capital Expenditure & R&D
- Capital allocation AI review
- Annual capital expenditure
- Investment intensity trends
- Capex and R&D intensity indicators
Balance Sheet
- Balance sheet AI review
- Assets, debt and equity
- Capital structure
- Liquidity and leverage
- Retained earnings
Dividends & Actions
- Cash dividends paid
- Dividend indicators
- Buybacks and issuance
- Combined shareholder returns
- Available corporate actions
Company Events
- Dated insider transactions
- Material company activity

Explore complete public research examples

These public assets show the complete asset profiles, fundamental datasets and analysis. Their findings concern those assets, not this report.